Pulse Biosciences (PLSE)
(Delayed Data from NSDQ)
$14.04 USD
+0.04 (0.29%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $13.99 -0.05 (-0.36%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Pulse Biosciences, Inc [PLSE]
Reports for Purchase
Showing records 1 - 19 ( 19 total )
Company: Pulse Biosciences, Inc
Industry: Medical - Instruments
Company: Pulse Biosciences, Inc
Industry: Medical - Instruments
Awaiting Clarity on New Commercial Strategy; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Pulse Biosciences, Inc
Industry: Medical - Instruments
Revamping Commercial Strategy in 2022; Lower PT to $8.50; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Pulse Biosciences, Inc
Industry: Medical - Instruments
SH Indication Uncertainty; Lower PT to $20; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Pulse Biosciences, Inc
Industry: Medical - Instruments
CellFX Marked a Significant Commercial Milestone; Lower PT to $43; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Pulse Biosciences, Inc
Industry: Medical - Instruments
Company: Pulse Biosciences, Inc
Industry: Medical - Instruments
Positive Feedback for CellFX Ahead of Full Launch; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Pulse Biosciences, Inc
Industry: Medical - Instruments
Controlled CellFX Launch on Track; Eventful 2021; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Pulse Biosciences, Inc
Industry: Medical - Instruments
CellFX Enters Commercialization Stage; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Pulse Biosciences, Inc
Industry: Medical - Instruments
FDA Approval Triggers CellFx Launch; Higher $46 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Pulse Biosciences, Inc
Industry: Medical - Instruments
CE Mark Approval Leads to an Imminent CellFX Launch; Higher $40 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Pulse Biosciences, Inc
Industry: Medical - Instruments
Inflection Expected in 2021 Pending CellFX approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Pulse Biosciences, Inc
Industry: Medical - Instruments
Making Progress on Regulatory Front; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Pulse Biosciences, Inc
Industry: Medical - Instruments
Expect CellFX 510(k) Filing in 3Q20; Upgrade to Buy With a $16 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Pulse Biosciences, Inc
Industry: Medical - Instruments
To Seek an Alternate 510 (k) Clearance of CellFX; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Pulse Biosciences, Inc
Industry: Medical - Instruments
CellFX Hits FDA Roadblock With Need for Additional Studies; Downgrade to Neutral With $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Pulse Biosciences, Inc
Industry: Medical - Instruments
CellFX Approval Expected in 4Q19; Promising Indication Expansion; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Pulse Biosciences, Inc
Industry: Medical - Instruments
CellFX Potential Approval in 4Q19; Adjusting PT to $26; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Pulse Biosciences, Inc
Industry: Medical - Instruments
Information Request From FDA Likely to Delay CellFX Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
|